prikaz prve stranice dokumenta Salvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split
  Download
PDF 477.02 KB
master's thesis
Salvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split
Split: University of Split, School of Medicine, 2018. urn:nbn:hr:171:390281
Radosevic, Sebastian
University of Split
School of Medicine

Institutional repository: MEFST Repository

Cite this document

Radosevic, S. (2018). Salvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:390281

Radosevic, Sebastian. "Salvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split." Master's thesis, University of Split, School of Medicine, 2018. https://urn.nsk.hr/urn:nbn:hr:171:390281

Radosevic, Sebastian. "Salvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split." Master's thesis, University of Split, School of Medicine, 2018. https://urn.nsk.hr/urn:nbn:hr:171:390281

Radosevic, S. (2018). 'Salvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split', Master's thesis, University of Split, School of Medicine, accessed 27 August 2024, https://urn.nsk.hr/urn:nbn:hr:171:390281

Radosevic S. Salvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split [Master's thesis]. Split: University of Split, School of Medicine; 2018 [cited 2024 August 27] Available at: https://urn.nsk.hr/urn:nbn:hr:171:390281

S. Radosevic, "Salvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split", Master's thesis, University of Split, School of Medicine, Split, 2018. Available at: https://urn.nsk.hr/urn:nbn:hr:171:390281

Metadata
TitleSalvage radiotherapy of prostate cancer : retrospective analysis of 10 years’ experience in the Department of oncology and radiotherapy University hospital of Split
Title (croatian)˝Salvage˝-radioterapija (SRT) karcinoma prostate, retrospektivna analiza desetgodišnjeg iskustva Klinike za onkologiju i radioterapiju Kliničkog bolničkog centra Split
AuthorSebastian Radosevic
MentorTomislav Omrčen (mentor)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2018, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract
Objectives: We evaluated the clinical outcomes of patients treated with salvage radiotherapy (SRT) after biochemical relapse regarding the biochemical control after surgery, overall survival (OS) and metastatic-free survival (MFS). Materials and Methods: A retrospective cohort study (from 2006 until 2015) using the data collected from patient charts in the Department of Oncology and Radiotherapy in Split with missing data requested from Zadar, Šibenik and Dubrovnik. A total of 124 patients treated with salvage radiotherapy after developing biochemical relapse following radical prostatectomy (RP) were included into this study. Results: The median follow-up from salvage radiotherapy to the 1.2.18 was 58 months with 68 years being the median age of the patients. Therapy was started after a median of 5.5 months. Out of the 124 patients, 68 started SRT with a PSA level below 0.7 ng/ml. 80 patients respond-ed to the therapy with drop in PSA of more than 90%. Progression after SRT was observed in 33 patients and 4 patients developed metastases. This leads to a median biochemical relapse-free survival (BRFS) of 26 months, OS of 53 months, an MFS of 52.5 months. The 5-year overall survival of the patients included is 91.7% (95%CI= 85.71 to 97.90); the 5-year biochemical relapse-free survival was 85.51% (95%CI = 76.68 to 94.33) and the 5-year metastases-free survival was 91.09% (95%CI = 85.00 to 97.35). A relationship was shown between lympho-vascular invasion and MFS (P=0.015) and OS (P=0.005). Perineural invasion (P=0.034) and the TNM stage (P=0.047) show a relation to OS. Other relationships were not observed. Conclusion: Patients treated with SRT show a good biochemical response after the therapy. If the surrounding tissues were not involved and the initial TNM stage is low, the outcomes im-prove leading to a better MFS and OS.
Abstract (croatian)
Ciljevi: Evaluacija ishoda liječenja pacijenata SRT kod biokemijskog recidiva nakon radikalne prostatektomije obzirom na biokemijsku kontrolu (PSA), ukupno preživljavanje (OS) i preživljavanje bez metastaza (MFS). Materijali i metode: Retrospektivna kohortna studija (od 2006 do 2015) na osnovu podataka dobivenih iz povijesti bolesti pacijenata s Klinike za onkologiju i radioterapiju u Splitu, te s odjela onkologije OB bolnica u Zadru, Šibeniku i Dubrovniku. Ukupno je u studiji obrađeno 124 pacijenta koji su liječeni SRT zbog biokemijskog recidiva nakon radikalne prostatektomije. Rezultati: Medijan praćenja nakon SRT je bio 58 mjeseci (do 01.02.2018), medijan dobi pacijenata iznosi 68 godina. Sa SRT se počelo u prosijeku nakon 5,5 mjeseci. Kod 68 pacijenata od ukupno 124, počelo se sa SRT kod vrijednosti PSA ispod 0,7 ng/ml. Kod 80 pacijenata je pala vrijednost PSA za više od 90%. Biokemijska progresija bolesti nakon SRT je primjećena kod 33 pacijenata, a u 4 pacijenta su se razvile presadnice. To odgovara medijanu preživljenja bez biokemijskog recidiva (bRFS) od 26 mjeseci, medijanu ukupnog preživljenja (OS) od 53 mjeseca i medijanu preživljenja bez metastaza (MFS) od 52,5 mjeseci. Stopa petogodišnjeg preživljenja iznosi 91,7% (95%CI= 85.71 do 97.90); petogodišnje preživljenje bez biokemijskog recidiva iznosi 85.51% (95%CI = 76.68 do 94.33) i petogodišnje preživljenje bez metastaza iznosi 91.09% (95%CI = 85.00 to 97.35). Postoji povezanost između limfovaskularne invazije i preživljavanja bez metastasa (MFS) (P=0,015) i ukupnog preživljavanja (OS) (P=0,005). Nadalje postoji povezanost perineuralne invazije (P=0,034) i TNM-stadija (P=0,047) s ukupnim preživljavanjem. Zaključci: Salvage-radioterapija kod pacijenata s biokemijskim rezidivom nakon radikalne prostatektomije uzrokuje pad vrijednosti PSA PSA i utječe na ukupno preživljenje, preživljenje bez biokemijske progresije i preživljenje bez pojave presadnica Izostanak tumorske infiltracije okolnog tkiva i niski inicijalni TNM-stadij poboljšavaju prognozu obzirom na preživljavanje bez metastaza (MFS) i ukupno preživljavanje (OS).
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:171:390281
Study programmeTitle: Medical Studies in English
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2018-10-15 11:45:33